These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 10561355

  • 1. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
    Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton CR.
    J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB.
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [Abstract] [Full Text] [Related]

  • 3. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH, Meyers PA.
    J Clin Oncol; 2001 Feb 01; 19(3):870-80. PubMed ID: 11157041
    [Abstract] [Full Text] [Related]

  • 4. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J, Société Française des Cancers de l'Enfant.
    J Clin Oncol; 2006 Aug 20; 24(24):3997-4002. PubMed ID: 16921053
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC.
    J Clin Oncol; 2012 Jul 10; 30(20):2457-65. PubMed ID: 22665534
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN).
    Lancet Oncol; 2017 Apr 10; 18(4):500-514. PubMed ID: 28259608
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
    Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG.
    J Clin Oncol; 2001 Jun 01; 19(11):2812-20. PubMed ID: 11387352
    [Abstract] [Full Text] [Related]

  • 14. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS].
    Fröhlich B, Ahrens S, Burdach S, Klingebiel T, Ladenstein R, Paulussen M, Zoubek A, Jürgens H.
    Klin Padiatr; 1999 Jun 01; 211(4):284-90. PubMed ID: 10472563
    [Abstract] [Full Text] [Related]

  • 15. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA.
    J Clin Oncol; 2016 Jan 10; 34(2):117-22. PubMed ID: 26503200
    [Abstract] [Full Text] [Related]

  • 16. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM.
    J Pediatr Hematol Oncol; 2001 May 10; 23(4):215-20. PubMed ID: 11846299
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
    Corbett R, Pinkerton R, Pritchard J, Meller S, Lewis I, Kingston J, McElwain T.
    Eur J Cancer; 1992 May 10; 28A(8-9):1324-8. PubMed ID: 1515243
    [Abstract] [Full Text] [Related]

  • 19. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voûte PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O.
    Eur J Cancer; 1998 Jun 10; 34(7):1050-62. PubMed ID: 9849454
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.